Should the FDA have rejected Contrave?
Posted by: admin on: October 13, 2011
by Daniel J. Carlat, MD
Recently, the FDA has rejected another anti-obesity drug, Contrave, because of concerns that it might cause heart attacks in patients who take it for years.
FDA’s excessive caution was motivated by its experience having been burned by the Fen-Phen fiasco. This was a weight loss drug widely prescribed in the 90s that was pulled from the market after studies showed it caused fatal lung and heart valve problems.
Recent MI Increases Risks of Surgery
Posted by: admin on: October 13, 2011
A recent heart attack remains a significant risk factor for complications and death after major surgery, despite advances in clinical management, researchers reported.
But the risk of a postoperative MI or death decreased substantially as the time between the first MI and the surgery increased, according to Christian de Virgilio, MD, of the Los Angeles Biomedical Research Institute in Torrance, Calif., and colleagues.
Physical Activity Guidelines May Improve Survival
Posted by: admin on: October 12, 2011
Meeting the recommendations set out in the federal 2008 Physical Activity Guidelines for Americans is associated with reduced all-cause mortality in U.S. adults,
Using data from the 1997 to 2004 National Health Interview Survey, and linked mortality records, the relative mortality risks were examined for 242,397 U.S. adults aged 18 years and older. Risks were examined separately for adults with and without chronic health conditions.
Osteoporosis management remains a challenge for endocrinologists
Posted by: admin on: October 12, 2011
Despite new guidelines and updated tools, diagnosing and treating patients with osteoporosis remains a challenge, a speaker said here.
Nelson B. Watts, MD, professor of medicine at the University of Cincinnati College of Medicine, said today “there are new guidelines on calcium and vitamin D, new recommendations for testing for postmenopausal osteoporosis and new concerns about old treatments.
Olmesartan/Amlodipine: a review of its use in the management of Hypertension
Posted by: admin on: October 12, 2011
Combination therapy is an effective strategy to increase antihypertensive efficacy in those patients with poor blood pressure (BP) control. In order to achieve BP targets, at least 75% of patients may require combination therapy, particularly in those patients with a high cardiovascular risk. Evidence from large, randomized controlled trials, and the European hypertension treatment guidelines is supportive of the use of an angiotensin receptor blocker (ARB) with a calcium channel blocker (CCB).
Search
- drchasrani: Difficult to get such a data, authenticated at that. Try Times of India online library
- rakesh pore: hi, where can i get genuine information about "10 most common drugs sold in india?" i want it for a local project
- nilesh dutta: sir, Plz give detail about MBA Sports Management Thanks and Regards
